A platform that aims to change outcomes for dogs diagnosed with cancer recently received $ 10 million in new funding to help the company grow and provide more dogs with access to precision treatments.
FidoCure uses genetic testing to determine what genetic mutation is behind a dog’s cancer. Upon completion of the tests, FidoCure will provide precision medicine reports with recommendations for individualized, targeted therapy using the latest scientific evidence available in both human and canine oncology. FidoCure is available nationwide through more than 200 participating veterinarians.
To learn more, visit fidocure.com.
